A review of the ethnic differences in breast cancer

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Brawley OW: Disaggregating the effects of race and poverty on breast cancer outcomes. J. Natl Cancer Inst.94(7),471–413 (2002).
  MedlineGoogle Scholar
• 2  Elledge RM, Clark GM, Chamness GC et al.: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J. Natl Cancer Inst.86(9),705–712 (1994).•• An early paper documenting differences in tumor biology between ethnic groups.
  Medline CASGoogle Scholar
• 3  Jatoi I, Anderson WF, Rao SR et al.: Breast cancer trends among black and white women in the United States. J. Clin. Oncol.23(31),7836–7841 (2005).• Documentation of widening disparity in breast cancer mortality between black and white women in the USA.
  MedlineGoogle Scholar
• 4  Adebamowo CA, Adekunle OO: Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br. J. Surg.86(5),665–668 (1999).
  Medline CASGoogle Scholar
• 5  Newman LA, Alfonso EA: Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital. Ann. Surg. Oncol.4(8),655–662 (1997).• Suggestion of ethnicity-related variation in primary breast tumor biology.
  Medline CASGoogle Scholar
• 6  Steele GD Jr.: The National Cancer Data Base report on colorectal cancer. Cancer74(7),1979–1989 (1994).
  MedlineGoogle Scholar
• 7  El-Tamer MB, Homel P, Wait BR: Is race a poor prognostic factor in breast cancer? J. Am. Coll. Surg.189(1),41–45 (1999).
  Medline CASGoogle Scholar
• 8  Joslyn SA, West MM: Racial differences in breast carcinoma survival. Cancer88(1),114–123 (2000).
  Medline CASGoogle Scholar
• 9  Newman LA, Bunner S, Carolin K et al.: Ethnicity related differences in the survival of young breast carcinoma patients. Cancer95(1),21–27 (2002).• Demonstrates that young African–American women with breast cancer have an increased mortality risk.
  MedlineGoogle Scholar
• 10  Jones BA, Kasl SV, Howe CL et al.: African–American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer101(6),1293–1301 (2004).
  MedlineGoogle Scholar
• 11  Gukas ID, Jennings BA, Mandong BM et al.: Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr. J. Med.24(3),209–213 (2005).
  Medline CASGoogle Scholar
• 12  Chang S, Parker SL, Pham T et al.: Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer82(12),2366–2372 (1998).
  Google Scholar
• 13  Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet360(9328),187–195 (2002).
  MedlineGoogle Scholar
• 14  Okobia M, Bunker C, Zmuda J et al.: Case–control study of risk factors for breast cancer in Nigerian women. Int. J. Cancer
  Google Scholar
• 15  Selaru FM, Yin J, Olaru A et al.: An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Res.64(5),1584–1588 (2006).• Identification of a biologically unique subgroup of estrogen receptor-positive breast cancers in African–American women.
  Google Scholar
• 16  Poola I, Clarke R, DeWitty R et al.: Functionally active estrogen receptor isoform profiles in the breast tumors of African–American women are different from the profiles in breast tumors of Caucasian women. Cancer94(3),615–623 (2002).• Identification of a biologically unique subgroup of estrogen receptor-positive breast cancers in African–American women.
  Medline CASGoogle Scholar
• 17  Carey LA, Perou CM, Livasy CA et al.: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA295(21),2492–2502 (2006).•• Recent study defining breast cancer subtypes and highlighting differences between ethnic groups that relate to survival.
  Medline CASGoogle Scholar
• 18  Ameyaw MM, Tayeb M, Thornton N et al.: Ethnic variation in theHER2 codon 655 genetic polymorphism previously associated with breast cancer. J. Hum. Genet.47(4),172–175 (2002).
  Medline CASGoogle Scholar
• 19  Vousden KH, X Lu: Live or let die: the cell's response to p53. Nat. Rev. Cancer2(8),594–604 (2002).
  Medline CASGoogle Scholar
• 20  Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update. Endocr. Relat. Cancer13(2),293–325 (2006).
  Medline CASGoogle Scholar
• 21  Feki A, Irminger-Finger I: Mutational spectrum ofp53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol.52(2),103–116 (2004).
  MedlineGoogle Scholar
• 22  Thor AD, Moore DH, II, Edgerton SM et al.: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst.84(11),845–855 (1992).
  Medline CASGoogle Scholar
• 23  Weston A. and Godbold HJ: Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ. Health Perspect. 105(Suppl.) 4,919–926 (1997).
  Google Scholar
• 24  Olopade O, Weber BL: Breast cancer genetics: toward molecular characterization of individuals at increased risk for breast cancer. Part I. In: Cancer Priniciples and Practice of Oncology Updates. De Vita T, Hellman S, Rosenberg SA (Eds). Vol. 12. 1–12 (1998).
  Google Scholar
• 25  Goffin JR, Chappuis PO, Begin LR et al.: Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer97(3),527–536 (2003).
  Medline CASGoogle Scholar
• 26  Foulkes WD: BRCA1 functions as a breast stem cell regulator. J. Med. Genet.41(1),1–5 (2004).
  Medline CASGoogle Scholar
• 27  Olopade OI, Fackenthal JD, Dunston G et al.: Breast cancer genetics in African–Americans. Cancer97(1 Suppl.),236–245 (2003).
  Medline CASGoogle Scholar
• 28  Nanda R, Schumm LP, Cummings S et al.: Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis ofBRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA294(15),1925–1933 (2005).
  Medline CASGoogle Scholar
• 29  Frank TS, Deffenbaugh AM, Reid JE et al.: Clinical characteristics of individuals with germline mutations in BRCA1 andBRCA2: analysis of 10,000 individuals. J. Clin. Oncol.20(6),1480–1490 (2002).
  Medline CASGoogle Scholar
• 30  Foulkes WD, Stefansson IM, Chappuis PO et al.: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst.95(19),1482–1485 (2003).
  Medline CASGoogle Scholar
• 31  Sorlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98(19),10869–10874 (2001).
  Medline CASGoogle Scholar
• 32  Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA100(14),8418–8423 (2003).•• Classification of breast cancers into subtypes representing biologically distinct entities.
  Medline CASGoogle Scholar
• 33  Wetzels RH, Holland R, van Haelst UJ et al.: Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am. J. Pathol.134(3),571–579 (1989).
  Medline CASGoogle Scholar
• 34  Arnes JB, Brunet JS, Stefansson I et al.: Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res.11(11),4003–4011 (2005).
  Medline CASGoogle Scholar
• 35  van de Rijn M, Perou CM, Tibshirani R et al.: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol.161(6),1991–1996 (2002).
  Medline CASGoogle Scholar
• 36  Rouzier R, Perou CM, Symmans WF et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res.11(16),5678–5685 (2005).• Identification of basal tumors using cDNA microarray analysis.
  Medline CASGoogle Scholar
• 37  Tsuda H, Takarabe T, Hasegawa F et al.: Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am. J. Surg. Pathol.24(2),197–202 (2000).
  Medline CASGoogle Scholar
• 38  Mehrotra J, Ganpat MM, Kanaan Y et al.: Estrogen receptor/progesterone receptor-negative breast cancers of young African–American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin. Cancer Res.10(6),2052–2057 (2004).
  Medline CASGoogle Scholar
• 39  Hernandez J, Balic I, Johnson-Pais TL et al.: Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J. Urol.175(2),523–527 (2006).
  Medline CASGoogle Scholar
• 40  Canter JA, Kallianpur AR, Parl FF et al.: Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African–American women. Cancer Res.65(17),8028–8033 (2005).
  Medline CASGoogle Scholar
• 41  Stackhouse BL, Williams H, Berry P et al.: Measurement of glut-1 expression using tissue microarrays to determine a race specific prognostic marker for breast cancer. Breast Cancer Res. Treat.93(3),247–253 (2005).
  Medline CASGoogle Scholar
• 42  Bradley CJ, Given CW, Roberts C: Race, socioeconomic status, and breast cancer treatment and survival. J. Natl Cancer Inst.94(7),490–496 (2002).
  MedlineGoogle Scholar
• 43  Lannin DR, Mathews HF, Mitchell J et al.: Impacting cultural attitudes in African–American women to decrease breast cancer mortality. Am. J. Surg.184(5),418–423 (2002).
  MedlineGoogle Scholar
• 44  Newman LA, Griffith KA, Jatoi I et al.: Meta-analysis of survival in African–American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J. Clin. Oncol.24(9),1342–1349 (2006).
  MedlineGoogle Scholar
• 45  Newman LA, Theriault R, Clendinnin N et al.: Treatment choices and response rates in African–American women with breast carcinoma. Cancer97(1 Suppl.),246–252 (2003).
  MedlineGoogle Scholar
• 46  Hershman D, McBride R, Jacobson JS et al.: Racial disparities in treatment and survival among women with early-stage breast cancer. J. Clin. Oncol.23(27),6639–6646 (2005).
  MedlineGoogle Scholar
• 47  Bonadonna G, Valagussa P, Moliterni A et al.: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med.332(14),901–906 (1995).
  Medline CASGoogle Scholar
• 48  Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med.304(1),10–15 (1981).
  Medline CASGoogle Scholar
• 49  Bickell NA, Wang JJ, Oluwole S et al.: Missed opportunities: racial disparities in adjuvant breast cancer treatment. J. Clin. Oncol.24(9),1357–1362 (2006).• Differences in receipt of appropiate adjuvant therapy between ethnic groups.
  MedlineGoogle Scholar
• 50  Dignam JJ, Redmond CK, Fisher B et al.: Prognosis among African–American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Cancer80(1),80–90 (1997).• Early detection and appropiate therapy reduced the disparity in mortality.
  Medline CASGoogle Scholar
• 51  Roach M III, Cirrincione C, Budman D et al.: Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J. Sci. Am.3(2),107–112 (1997).
  MedlineGoogle Scholar
• 52  Dignam JJ: Differences in breast cancer prognosis among African–American and Caucasian women. CA Cancer J. Clin.50(1),50–64 (2000).
  Medline CASGoogle Scholar
• 53  Briele HA Jr, Walker MJ, Wild L et al.: Results of treatment of stage I–III breast cancer in black Americans. The Cook County Hospital experience, 1973–1987. Cancer65(5),1062–1071 (1990).
  Google Scholar
• 54  Bain BJ: Ethnic and sex differences in the total and differential white cell count and platelet count. J. Clin. Pathol.49(8),664–666 (1996).
  Medline CASGoogle Scholar
• 55  Smith K, Wray L, M. Klein-Cabral et al.: Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients. Clin. Breast Cancer6(3),260–269 (2005).
  MedlineGoogle Scholar
• 56  Gail MH, Costantino JP, Bryant J et al.: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J. Natl Cancer Inst.91(21),1829–1846 (1999).
  Medline CASGoogle Scholar
• 57  McCaskill-Stevens W, Wilson J, Bryant J et al.: Contralateral breast cancer and thromboembolic events in African–American women treated with tamoxifen. J. Natl Cancer Inst.96(23),1762–1769 (2004).
  Medline CASGoogle Scholar
• 58  Albain K, Unger, JM, Hurchins LF et al.: Outcome of African–Americans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. (abstr 21) San Antonio Breast Cancer Symposium. 2003. San Antonio, TX, USA.
  Google Scholar
• 59  Chlebowski RT, Chen Z, Anderson GL et al.: Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J. Natl Cancer Inst.97(6),439–448 (2005).
  MedlineGoogle Scholar
• 60  Taylor AL, Ziesche S, Yancy C et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med.351(20),2049–2057 (2004).
  Medline CASGoogle Scholar
• 61  Yancy CW, Fowler MB, Colucci WS et al.: Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N. Engl. J. Med.344(18),1358–1365 (2001).
  Medline CASGoogle Scholar
• 62  Exner DV, Dries DL, Domanski MJ et al.: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N. Engl. J. Med.344(18),1351–1357 (2001).
  Medline CASGoogle Scholar
• 63  Lamba JK, Lin YS, Schuetz EG et al.: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev.54(10),1271–1294 (2002).
  Medline CASGoogle Scholar
• 64  Tucker AN, Tkaczuk KA, Lewis LM et al.: Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett.217(1),61–72 (2005).
  Medline CASGoogle Scholar
• 65  Guillemette C, Millikan RC, Newman B et al.: Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African–Americans. Cancer Res.60(4),950–956 (2000).
  Medline CASGoogle Scholar
• 66  Li Y, Millikan RC, Bell DA et al.: Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among African–American and white women. Breast Cancer Res.6(4),R460–R473 (2004).
  Medline CASGoogle Scholar
• 67  Millikan RC, Player J, de Cotret AR et al.: Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case–control study of African–Americans and whites. Breast Cancer Res.6(4),R264–R274 (2004).
  Medline CASGoogle Scholar
• 68  Porter PL, Lund MJ, Lin MG et al.: Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer100(12),2533–2542 (2004).
  MedlineGoogle Scholar
• 69  Shiao YH, Chen VW, Scheer WD et al.: Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res.55(7),1485–1490 (1995).
  Medline CASGoogle Scholar